31 March 2017

MaxCyte, Inc.

MaxCyte, Inc. (LSE: MXCT), a US-based company dedicated to driving commercialisation of next-generation, cell-based medicines, announced an equity placing that raised gross proceeds of £20 million. 

The funding will be used to further the company's programme for Ovarian Cancer and Acute Myeloid Leukemia through its IND application and into clinical studies; and to expand into new indications by financing pre-clinical and IND enabling studies in advance of possible clinical studies.  LGB Investments worked with the company's broker, Panmure Gordon, to expand distribution of the issue.

Recent Articles

28 April 2021

The start of a supercycle?

With the UK government last year announcing that green hydrogen was to be central to the country’s ‘green industrial revolution' and the EU’s hydrogen roadmap forecasting €500bn being invested in the transition to a hydrogen-based economy by 2050, Read more

News & Insights

26 April 2021

Time Finance - Latest Issue

We are pleased to announce the successful completion of a £2 million note issuance under the Time Finance plc (formerly 1pm plc) MTN programme. 

Read more

Deals

20 April 2021

Market Commentary - Q1 2021

Q1 2021 was marked in the UK, and the US which continues to set the tone for world markets, by cautious optimism that the vaccine rollout will work, and that economies will restart. Read more

News & Insights